Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

Phase II results for Cybin’s psilocin therapy showed remission rates of 71%, but just eight patients made it to the 12-month ...

Wegovy is being made available to Chinese patients five months after its approval in the country. Novo will sell the medicine ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...

SignalChem Biotech provides diverse recombinant Tau proteins for research, helping advance tau-targeted therapies that may ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...